https://www.selleckchem.com/pr....oducts/cdk2-inhibito
4±1.8, n=9), but substantially improved survival (93% vs. 57% DMSO). There were no differences between DMSO and PKT100 bleomycin mice in pulmonary inflammation or remodelling. However RV hypertrophy was reduced in PKT100 mice. Bleomycin decreased echocardiographic surrogates of RV systolic performance (FAC, s', which were significantly improved with PKT100. Four genes involved in RV remodelling were differentially expressed between DMSO and PKT100-treated groups. Conclusions The novel P2X7R inhibitor, PKT100, attenuates RV hy
Like
Comment
Share
